(Q43134067)

English

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

scientific article published on 28 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study (English)

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Gerhard Ehninger

14

object named as

G Ehninger

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Martin Bornhäuser

9

object named as

M Bornhäuser

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Uwe Platzbecker

1

object named as

U Platzbecker

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

author name string

F Braulke

2

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

A Kündgen

3

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

K Götze

4

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

G Bug

5

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

C Schönefeldt

6

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

K Shirneshan

7

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

C Röllig

8

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

R Naumann

10

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

J Neesen

11

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

A Giagounidis

12

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

W-K Hofmann

13

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

U Germing

15

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

D Haase

16

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

M Wermke

17

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

publication date

28 January 2013

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

27

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

6

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

1403-1407

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

https://scigraph.springernature.com/pub.10.1038/leu.2013.26

0 references

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Clinical effect of point mutations in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

15 August 2018

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

15 August 2018

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

15 August 2018

PET scans: when and how?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.26

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.26

21 January 2018

Identifiers

10.1038/LEU.2013.26

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43134067&oldid=1981400394"